​

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALNY Stock Forecast

Alnylam Pharmaceuticals (ALNY) stock forecast, based on 50 Wall Street analysts, predicts a 12-month average price target of $465.83, with a high of $535.00 and a low of $370.00. This represents a -2.66% decline from the last price of $478.58.

$100 $190 $280 $370 $460 $550 High: $535 Avg: $465.83 Low: $370 Last Closed Price: $478.58

ALNY Stock Rating

Alnylam Pharmaceuticals stock's rating consensus is Buy, based on 50 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 38 Buy (76.00%), 11 Hold (22.00%), 1 Sell (2.00%), and 0 Strong Sell (0.00%).

Buy
Total 50 1 11 38 Strong Sell Sell Hold Buy Strong Buy

ALNY Price Target Upside V Benchmarks

TypeNameUpside
StockAlnylam Pharmaceuticals-2.66%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4610
Avg Price Target$488.75$465.83$418.80
Last Closing Price$478.58$478.58$478.58
Upside/Downside2.13%-2.66%-12.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2581471-30
Sep, 2581671-32
Aug, 2591571133
Jul, 25111371133
Jun, 25121271133
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 22, 2025Cantor Fitzgerald$450.00$474.00-5.06%-5.97%
Oct 17, 2025Truist Financial$535.00$479.1911.65%11.79%
Oct 06, 2025Michael UlzMorgan Stanley$475.00$456.354.09%-0.75%
Oct 06, 2025Paul MatteisStifel Nicolaus$495.00$456.358.47%3.43%
Sep 05, 2025Kostas BiliourisBMO Capital$470.00$452.813.80%-1.79%
Jul 29, 2025Raymond James$370.00$330.5511.93%-22.69%
Jul 21, 2025Danielle BrillTruist Financial$385.00$324.4918.65%-19.55%
Jun 24, 2025Kostas BiliourisBMO Capital$360.00$325.0010.77%-24.78%
Mar 21, 2025Scotiabank$338.00$283.3419.29%-29.37%
Jan 07, 2025William PickeringBernstein$310.00$235.9531.38%-35.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 05, 2025BMO CapitalOutperformOutperformhold
Sep 02, 2025CitigroupBuyBuyhold
Aug 04, 2025OppenheimerPerformOutperformupgrade
Aug 04, 2025Wolfe ResearchNegativePeer Performupgrade
Jun 24, 2025BMO CapitalOutperformOutperformhold
Mar 21, 2025ScotiabankOutperformOutperformhold
Jan 07, 2025BernsteinOutperformOutperformhold
Oct 24, 2024Canaccord GenuityBuyBuyhold
Oct 21, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.46$-7.20$-9.30$-3.52-----
Avg Forecast$-7.20$-6.44$-8.95$-3.48$-2.10$-1.04$2.91$6.52$12.25
High Forecast$-6.05$-5.41$-7.68$-2.38$0.75$4.40$9.93$19.04$15.89
Low Forecast$-8.50$-7.61$-10.93$-4.20$-3.77$-11.85$-1.93$2.05$10.34
Surprise %3.61%11.80%3.91%1.15%-----

Revenue Forecast

$0 $2B $3B $5B $6B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$492.85M$844.29M$1.04B$1.83B$2.25B----
Avg Forecast$475.26M$820.81M$1.01B$1.83B$2.24B$2.65B$3.54B$4.54B$5.85B
High Forecast$541.27M$934.80M$1.19B$1.88B$2.27B$3.06B$3.55B$4.61B$7.19B
Low Forecast$416.86M$719.95M$902.76M$1.77B$2.20B$2.40B$3.53B$4.47B$5.15B
Surprise %3.70%2.86%2.38%0.12%0.35%----

Net Income Forecast

$-2B $-700M $100M $900M $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-858.28M$-852.82M$-1.13B$-440.24M$-278.16M----
Avg Forecast$-777.85M$-723.17M$-770.44M$-440.24M$-332.26M$-196.87M$330.06M$942.06M$1.53B
High Forecast$-622.28M$-578.53M$-616.35M$-352.19M$94.21M$549.62M$1.24B$2.38B$1.99B
Low Forecast$-933.41M$-867.80M$-924.53M$-528.29M$-471.06M$-1.48B$-240.59M$255.91M$1.29B
Surprise %10.34%17.93%46.82%--16.28%----

ALNY Forecast FAQ

Is Alnylam Pharmaceuticals stock a buy?

Alnylam Pharmaceuticals stock has a consensus rating of Buy, based on 50 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 38 Buy, 11 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Alnylam Pharmaceuticals is a favorable investment for most analysts.

What is Alnylam Pharmaceuticals's price target?

Alnylam Pharmaceuticals's price target, set by 50 Wall Street analysts, averages $465.83 over the next 12 months. The price target range spans from $370 at the low end to $535 at the high end, suggesting a potential -2.66% change from the previous closing price of $478.58.

How does Alnylam Pharmaceuticals stock forecast compare to its benchmarks?

Alnylam Pharmaceuticals's stock forecast shows a -2.66% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Alnylam Pharmaceuticals over the past three months?

  • October 2025: 26.67% Strong Buy, 46.67% Buy, 23.33% Hold, 3.33% Sell, 0% Strong Sell.
  • September 2025: 25.00% Strong Buy, 50.00% Buy, 21.88% Hold, 3.12% Sell, 0% Strong Sell.
  • August 2025: 27.27% Strong Buy, 45.45% Buy, 21.21% Hold, 3.03% Sell, 3.03% Strong Sell.

What is Alnylam Pharmaceuticals’s EPS forecast?

Alnylam Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.04, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $2.91 in 2026, $6.52 in 2027, and $12.25 in 2028.

What is Alnylam Pharmaceuticals’s revenue forecast?

Alnylam Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $2.65B, reflecting a 17.76% increase from the reported $2.25B in 2024. The forecast for 2026 is $3.54B, followed by $4.54B for 2027, and $5.85B for 2028.

What is Alnylam Pharmaceuticals’s net income forecast?

Alnylam Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-197M, representing a -29.22% decrease from the reported $-278M in 2024. Projections indicate $330.06M in 2026, $942.06M in 2027, and $1.53B in 2028.